Form 10-K · Annual report
ResMed| 10-K, filed Aug 13, 2026
- Filed
- CIK
- 0000943819
- Accession no.
- 0000943819-26-000047
Summary
ResMed reported fiscal 2026 net revenue of $5.65 billion, up 10% from $5.15 billion a year earlier, and net income of $1.52 billion, or $10.43 per diluted share. The company acquired Noctrix Health, whose FDA De Novo-classified device treats restless legs syndrome, and agreed to sell its MatrixCare business for $490 million in cash, a deal expected to close in the first quarter of fiscal 2027.
Key points
- Net revenue rose 10% to $5,653 million in the year ended June 30, 2026, an 8% increase on a constant-currency basis, with Sleep and Breathing Health up 10% to $4,978 million and Residential Care Software up 5% to $676 million.
- Net income was $1,523 million, or $10.43 per diluted share, compared with $1,401 million, or $9.51 per diluted share, in fiscal 2025; operating cash flow was $1.8 billion and cash and equivalents totaled $1.5 billion.
- Research and development spending was $378 million, or 6.7% of net revenues.
- The MatrixCare business represented about $220 million of revenue and about $28 million of operating profit in fiscal 2026, and was classified as held for sale as of June 30, 2026; ResMed paid $0.60 per share in quarterly dividends, totaling $350 million.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 7 MANAGEMENT’S DISCUSSION Overview Management’s discussion and analysis of financial condition and results of operations, or the MD&A, is intended to help the reader understand our results of operations and financial condition. It is provided as a supplement to, and should be read in conjunction with, the consolidated financial statements and notes included in this report. We are a global leader in digital health and cloud-connected medical devices. We design innovative technology with the intention to empower people to live happier, healthier lives. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.